Skip to content

NHMRC Research Fellow; Co-head, Leukaemia and Cancer Genetics

MB ChB (Hons) MRCPCH FRACP PhD

Areas of research expertise: Preclinical and clinical leukaemia research

Dr Kotecha is a highly-qualified clinician-scientist. He obtained his MB ChB degree with honours from the University of Leicester, England in 2002. He obtained his postgraduate clinical qualifications from both the Royal College of Paediatrics and Child Health (U.K.) and the Royal Australasian College of Physicians and has been working as a Consultant in Child and Adolescent Haematology/Oncology in Perth, Western Australia (WA) since 2012. His laboratory-based PhD was conferred by the University of Western Australia and awarded a place on the Dean’s list in recognition of an outstanding thesis across all disciplines. He has raised over two million dollars in research support as CIA and has authored over 30 original research articles. He was named the 2017 Cancer Council of WA Early Career Researcher of the year and has subsequently been awarded a National Health and Medical Research Council Fellowship (2018-2021) to co-lead the WA Paediatric Leukaemia and Cancer Genetics preclinical research program. Dr Kotecha is an integral member of the Children’s Oncology Group and the international BFM Study Group, which are responsible for the design and implementation of clinical trials for children with leukaemia worldwide. Dr Kotecha is a member of the international INTERFANT acute lymphoblastic leukaemia committee, tasked with design and implementation of global clinical trials for babies diagnosed less than one year of age with acute lymphoblastic leukaemia. He is also the clinical lead for paediatric leukaemia and lymphoma for WA, representing the state at a national level within the Australian and New Zealand Children’s Haematology/Oncology Group Leukaemia and Lymphoma subcommittee. Within these roles, he is also responsible for strategic planning and engagement with key stakeholders to ensure appropriate delivery of services and equitable access to medicines for children with leukaemia in Australia. Ultimately, he envisages taking outstanding results from his preclinical research program to these national and international collaborative groups, facilitating the translation of novel biomarkers and efficacious agents into frontline clinical trials, to improve the outcome for children suffering from leukaemia.